Trombólisis local en tromboembolismo pulmonar

Device Evolution Also Impacts on Valve in Valve

TAVR to treat dysfunctional biological prosthetics (ViV) with the last generation self-expandable supra-annular prosthetic offers excellent results both clinical and hemodynamic. In addition, there were additional reductions of paravalvular regurgitation compared against the original models.  The present registry published in JAHA is the most extensive to treat this issue and replicate outcomes from the clinical<a href="https://solaci.org/en/2021/10/21/device-evolution-also-impacts-on-valve-in-valve/" title="Read more" >...</a>

Failed Aortic Bioprosthesis: Valve in Vale or Repeat Surgery?

The Valve in Valve (ViV) technique seems to be a better option than repeat surgery for failed aortic bioprosthesis. While this strategy lacks long-term evidence to address issues such as durability, it is considered as an option especially for young patients. ViV to treat failed surgical bioprosthesis has shown lower in-hospital mortality compared with repeat<a href="https://solaci.org/en/2021/10/20/failed-aortic-bioprosthesis-valve-in-vale-or-repeat-surgery/" title="Read more" >...</a>

Resonancia vs FFR en lesiones no culpables del infarto

New Markers of Aortic Stenosis Define Asymptomatic Patients

Asymptomatic aortic stenosis has been keeping us in tense stillness. However, there are new markers capable of identifying patients that might benefit from earlier intervention. In this regard, cardiovascular magnetic resonance (CMR) has been gaining its well-deserved place in cardiology and now more specifically in aortic stenosis.  This study sought to validate CMR markers of<a href="https://solaci.org/en/2021/08/19/new-markers-of-aortic-stenosis-define-asymptomatic-patients/" title="Read more" >...</a>

Post-dilatación de válvulas autoexpandibles

Self-Expanding Valve in Extreme Surgical Risk After 5 Years

Patients with aortic stenosis and extreme surgical risk have extremely high mortality due to known comorbidities. The short-term benefit of transcatheter aortic valve replacement (TAVR) with self-expanding valve is clear, and it warrants the procedure in this challenging population. While elderly patients with comorbidities who are at extreme surgical risk might be eligible for TAVR,<a href="https://solaci.org/en/2021/06/24/self-expanding-valve-in-extreme-surgical-risk-after-5-years/" title="Read more" >...</a>

EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies. This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress and<a href="https://solaci.org/en/2021/05/27/europcr-2021-evolut-low-risk-two-year-results-of-the-self-expanding-valve-in-low-risk-patients/" title="Read more" >...</a>

TAVR vs. the Least Invasive Surgically Implanted Valve

Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional bioprostheses, which require several stitches. These valves, which shorten surgical times, could compete with transcatheter-implanted valves (transcatheter aortic valve replacement, TAVR). The German Aortic Valve Registry analyzed 16,473 patients who underwent surgical aortic valve replacement with either a current-generation<a href="https://solaci.org/en/2021/04/19/tavr-vs-the-least-invasive-surgically-implanted-valve/" title="Read more" >...</a>

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. However, surgeons argue that these cases fail to consider patients from daily clinical practice, but rather include a population that has been carefully selected for randomized trials. Patients with non-tricuspid aortic stenosis, with severe<a href="https://solaci.org/en/2021/03/25/surgeons-claim-on-low-risk-patients-with-aortic-stenosis/" title="Read more" >...</a>

El estudio SOURCE 3 confirma los buenos resultados de la válvula SAPIEN 3 a un año de seguimiento

High Deployment: Also Trending with Balloon Expandable Valves

Conventional implantation of balloon expandable SAPIEN-3 results in a final 70:30 or 80:20 ratio of the valve in the aorta/left ventricular outflow tract. This comes with permanent pacemaker implantation rates of approximately 10%. Higher deployment might translate into lower rates of conduction abnormalities and pacemaker implantation.   The study compared a cohort of 1028 consecutive patients; 406<a href="https://solaci.org/en/2021/03/25/high-deployment-also-trending-with-balloon-expandable-valves/" title="Read more" >...</a>

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Cusp Overlap for Higher CoreValve Implantation

Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker implantation. Valve implantation 3 to 5 mm below the aortic annulus in a projection coaxial to the device is recommended. The problem is this is rarely in the annular plane of the valve. Ideal annular plane projection is<a href="https://solaci.org/en/2021/03/25/cusp-overlap-for-higher-corevalve-implantation/" title="Read more" >...</a>

Enfermedad pulmonar y TAVI, solo se beneficia un grupo reducido de pacientes

Sapien Valve Keeps Delivering in Jobs for Which It Was Not Designed

We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement. Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has<a href="https://solaci.org/en/2020/12/16/sapien-valve-keeps-delivering-in-jobs-for-which-it-was-not-designed/" title="Read more" >...</a>